A family-based analysis led to an X chromosome variant in MAGEC3 that appeared to contribute to early-onset ovarian cancer risk in sisters and their paternal grandmothers.
Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
LSU Health New Orleans and OmniSeq will collaborate to offer next-generation sequencing-based tumor profiling services to the institution's oncologists.
OmniSeq's goal is to make cancer genomic testing available to institutions, including comprehensive cancer centers, oncology practices, and community oncology groups.
NEW YORK (GenomeWeb) – Roswell Park Cancer Institute today said that the New York State Department of Health has granted approval for the institute to test cancer patients using its OmniSeq Target molecular diagnostic test.
NEW YORK (GenomeWeb) – The board of directors of New York State's development agency has approved $105 million in funding to establish the NYS Genomic Medicine and Big Data Center (GMBDC), a genomics data partnership that will connect institutions in Buffalo with the New York Genome Center, Gov.
NEW YORK (GenomeWeb News) – Roswell Park Cancer Institute is investing $18.5 million to fund the launch of a new Center for Personalized Medicine (CPM) at its campus in Buffalo, according to the office of NY Governor Andrew Cuomo.
New York State plans to fund a two-year, $5.1 million sequencing pilot project of 1,000 residents in Western New York under its Regional Economic Development Council Initiative.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
